This placebo-controlled, randomised trial (n=90) investigates the efficacy of a single infusion of ketamine combined with magnesium sulphate in treating refractory chronic cluster headache (CCH).
Chronic cluster headache is a rare primary headache disorder characterised by frequent attacks lasting over a year with little to no remission. The study aims to confirm previous findings suggesting that the combination of ketamine and magnesium can reduce the frequency of attacks in patients with drug-resistant CCH.
Participants will be randomly assigned to receive either the experimental treatment or a control, with outcomes measured in terms of the proportion of patients experiencing at least a 50% reduction in daily attacks. The study is conducted across multiple locations in France and is estimated to be completed by December 2024.
Trial Details
Trial Number